프레스티지바이오파마

950210KOSPI자연과학 및 공학 연구개발업

46.8 / 100

Reference Date: 2026-06-10

Financial Score11.5 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, ROE is below the industry average. Plunged 16.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Prestige BioPharma is a biopharmaceutical company specializing in biosimilars and monoclonal antibody drug development. Its Herceptin biosimilar HD201 received a positive opinion from the European Medicines Agency (EMA) in 2024, while Avastin biosimilar HD204 and Humira biosimilar PBP1502 are in development. The company's pancreatic cancer treatment antibody drug PBP1510 holds patents in 13 countries, and its CTHRC1-targeting antibody drug PBP1710 is also in development.

Number of Employees

67people

Average Salary

53.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

134768.35Industry Average 62.700.0Point

2149.4x industry avg (risky)

PBR

—Industry Average 3.243.5Point

ROE

0.80Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

14.17Industry Average 7.310.5Point

1.9x industry avg (risky)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1098.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -4.9% (improving, 2yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 85

Positive
프레스티지바이오파마IDC, 보건복지부 ‘첨단바이오 융합 인재 양성사.....
프레스티지바이오파마IDC가 보건복지부의 첨단바이오 인재 양성사업 기관으로 선정되어 혁신적인 인재 육성에 기여하며 기업의 미래 성장 가능성을 높임.
Positive
“어나프라주 품절급 인기”…비보존제약, 12만 바이알 추가 생산에 .....
프레스티지바이오파마의 추가 생산 계획 발표로 인해 기업의 성장 가능성이 높아져 긍정적인 시장 반응을 보임.
Positive
프레스티지바이오파마, 췌장암 신약 ‘PBP1510’ 임상 2a상 준비 ...
프레스티지바이오파마가 췌장암 신약 PBP1510의 임상 2a상 진행을 위한 준비를 완료하고 ESMO 학회에 초록을 제출하며 긍정적인 임상 진행 기대감을 높였다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 6,670Won52-week high 19,91052-week low 6,530

1-month return0.0Point

1m -16.73% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-29